News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zealand Pharma Informs of Commercial and Regulatory Status Updates Provided by Sanofi (France) (SAN.PA) on Lyxumia® for Type 2 Diabetes


6/24/2013 9:16:23 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that Sanofi (SANF.PA) today provided an update on the status for Lyxumia® and the Lantus®/Lyxumia® combination product. Lyxumia® (lixisenatide), the first once-daily prandial GLP-1 agonist for the treatment of adults with Type 2 diabetes, is a Zealand discovered peptide drug. Worldwide rights to develop and sell lixisenatide are exclusively licensed to Sanofi, covering also its use in combination treatments, including combinations with Lantus®, Sanofi’s leading diabetes product and the world’s most prescribed basal insulin product.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES